EVT:NYE-Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest (USD)

ETF | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 22.32

Change

-0.08 (-0.36)%

Market Cap

USD 1.46B

Volume

0.13M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The Funds investment objective is to provide a high level of after-tax total return consisting primarily of tax-advantaged dividend income and capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its total assets in dividend-paying common and preferred stocks. The Fund may invest in common and preferred stocks of both domestic and foreign issuers. The Fund may invest up to 30% of its total assets in securities rated below investment grade.

Inception Date: 30/09/2003

Primary Benchmark: Russell 1000 Value TR USD

Primary Index: Morningstar Mod Tgt Risk TR USD

Gross Expense Ratio: 1.47%

Management Expense Ratio:

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-19 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Mer Price(Change) Market Cap
ZTS Zoetis Inc 0.00 %

+8.73 (+5.51%)

USD 66.94B
TAK Takeda Pharmaceutical Co Ltd A.. 0.00 %

+0.08 (+0.61%)

USD 41.54B
HLN Haleon plc 0.00 %

-0.03 (-0.36%)

USD 37.53B
TEVA Teva Pharma Industries Ltd ADR 0.00 %

+0.10 (+0.72%)

USD 15.97B
RDY Dr. Reddy’s Laboratories Ltd.. 0.00 %

+0.80 (+1.08%)

USD 11.85B
CTLT Catalent Inc 0.00 %

+0.34 (+0.61%)

USD 10.04B
ELAN Elanco Animal Health 0.00 %

+0.32 (+2.43%)

USD 6.40B
PRGO Perrigo Company PLC 0.00 %

+0.16 (+0.49%)

USD 4.26B
HYPMY Hypera SA 0.00 %

+0.37 (+6.89%)

USD 3.81B
PBH Prestige Brand Holdings Inc 0.00 %

+0.14 (+0.20%)

USD 3.43B

ETFs Containing EVT

FCEF First Trust Income Opport.. 0.00 % 0.85 %

+0.11 (+-1.17%)

USD 0.03B
E908:F Lyxor 1 - TecDAX UCITS ET.. 0.00 % 0.00 %

-0.23 (-1.17%)

USD 0.08B
EXS2:F iShares TecDAX UCITS ETF .. 0.00 % 0.00 %

-0.24 (-1.17%)

USD 0.73B
E908:XETRA Lyxor 1 TecDAX (DR) UCITS.. 0.00 % 0.00 %

-0.23 (-1.17%)

USD 0.09B
EXS2:XETRA iShares TecDAX UCITS ETF .. 0.00 % 0.00 %

-0.24 (-1.17%)

USD 0.77B
EXIB:XETRA iShares TecDAX® UCITS ET.. 0.00 % 0.00 %

-0.05 (-1.17%)

USD 0.77B
CB1TX:SW Lyxor 1 TecDAX (DR) UCITS.. 0.00 % 0.00 %

-0.39 (-1.17%)

USD 0.09B
TDXPEX:SW iShares TecDAX® UCITS ET.. 0.00 % 0.00 %

-0.34 (-1.17%)

USD 5,933.97B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.31% 63% D 53% F
Dividend Return 2.01% 100% F 81% B-
Total Return 2.32% 75% C 59% D-
Trailing 12 Months  
Capital Gain -2.19% 50% F 35% F
Dividend Return 7.17% 100% F 83% B
Total Return 4.98% 50% F 44% F
Trailing 5 Years  
Capital Gain -4.57% 69% C- 43% F
Dividend Return 38.64% 100% F 92% A
Total Return 34.07% 77% C+ 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 0.88% 56% F 44% F
Dividend Return 8.42% 69% C- 61% D-
Total Return 7.53% 100% F 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 24.36% 63% D 47% F
Risk Adjusted Return 34.56% 75% C 58% F
Market Capitalization 1.46B 44% F 71% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.